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Background: To integrate 3D MR spectroscopy imaging (MRSI) in the treatment planning system (TPS) for
glioblastoma dose painting to guide simultaneous integrated boost (SIB) in intensity-modulated radiation therapy
(IMRT).
Methods: For sixteen glioblastoma patients, we have simulated three types of dosimetry plans, one conventional
plan of 60-Gy in 3D conformational radiotherapy (3D-CRT), one 60-Gy plan in IMRT and one 72-Gy plan in SIB-IMRT.
All sixteen MRSI metabolic maps were integrated into TPS, using normalization with color-space conversion and
threshold-based segmentation. The fusion between the metabolic maps and the planning CT scans were assessed.
Dosimetry comparisons were performed between the different plans of 60-Gy 3D-CRT, 60-Gy IMRT and 72-Gy
SIB-IMRT, the last plan was targeted on MRSI abnormalities and contrast enhancement (CE).
Results: Fusion assessment was performed for 160 transformations. It resulted in maximum differences <1.00 mm
for translation parameters and ≤1.15° for rotation. Dosimetry plans of 72-Gy SIB-IMRT and 60-Gy IMRT showed a
significantly decreased maximum dose to the brainstem (44.00 and 44.30 vs. 57.01 Gy) and decreased high
dose-volumes to normal brain (19 and 20 vs. 23% and 7 and 7 vs. 12%) compared to 60-Gy 3D-CRT (p < 0.05).
Conclusions: Delivering standard doses to conventional target and higher doses to new target volumes
characterized by MRSI and CE is now possible and does not increase dose to organs at risk. MRSI and CE
abnormalities are now integrated for glioblastoma SIB-IMRT, concomitant with temozolomide, in an ongoing
multi-institutional phase-III clinical trial. Our method of MR spectroscopy maps integration to TPS is robust and
reliable; integration to neuronavigation systems with this method could also improve glioblastoma resection or
guide biopsies.
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Glioblastoma multiforme (GBM) is the most frequent
malignant primary brain tumor in adult patients. Prognosis
remains poor with a median survival of 14.6 months follow-
ing treatment with surgery, external beam radiotherapy
(RT), and chemotherapy [1]. Although adjuvant RT
increases overall survival, whatever the age or Karnofsky/
OMS status of the patient, more than 90% of failures occur
within the irradiated volumes [2]. This suggests that the
dose conventionally delivered is not sufficient. Therefore,
there is interest in increasing the dose to specific and more
aggressive parts of the tumor while sparing normal tissue,
using new technologies such as intensity-modulated radi-
ation therapy (IMRT) [3,4].
As conventional MRI morphological sequences are in-
sufficient to determine the potential target for a dose
escalation [5] other types of imaging are needed, such as
metabolic imaging [6,7]. The modality of proton mag-
netic resonance spectroscopy imaging (MRSI) is a rele-
vant tool to define new targets as it can characterize the
biochemical, metabolic and pathological changes in
brain tissues [8-11] with the analysis of 3D-multi-voxel
array within the MRI lesions and the surrounding nor-
mal tissue. MRSI data have been correlated with histo-
pathology and can assess the residual disease after
surgical resection in high-grade gliomas [12]. In
addition, MRSI parameters were also found to be pre-
dictive of survival [13,14].
The most common observation in glioblastoma is the
peak corresponding to the choline-containing com-
pounds (Cho) which increases with membrane prolifera-
tion, thus reflecting tumor presence and aggressiveness
[15]. For relative quantification of MR spectroscopic
data, the ratio of Cho over N-acetyl-aspartate (NAA, a
neurotransmitter only found in normal functioning
neurons), is used [16]. The volumes corresponding to
MRSI abnormalities and contrast enhancement (CE)
were found to predict relapse patterns [17,18], in con-
cordance with our results obtained from a prospective
trial [19]. MRSI (index of Cho/NAA ≥ 2) could predict
the extent of anatomical and metabolic relapse after
radio-chemotherapy in patients with glioblastoma [20].
Therefore, these volumes represent potential radioresis-
tant areas on which subvolume boosting [21] or dose
painting by contours [22] is possible.
There are two main issues for the integration of
MRSI into a RT treatment planning system (TPS).
Firstly, MRSI images obtained from MRI scanners are
MR spectroscopic maps overlaid on corresponding ana-
tomical MR images. These images do not conform to
DICOM standards,they are not compatible (contrarily
to conventional MR images) for automatic image fusion
with the planning CT scans. Secondly, the escalation in
radiation dose from simultaneous integrated boost(SIB) should be carefully evaluated, in particular for
organs at risk (OAR).
We performed this study in order to prepare a multi-
institutional phase III prospective clinical trial of glio-
blastoma dose painting guided by MRSI. This trial will
compare two RT treatments in concomitance with
temozolomide: one delivering 60 Gy on conventional
target volume and the other delivering 60 Gy on conven-
tional target volume and a SIB of 72 Gy on a new target
volume specific to MRSI.
In this paper, we propose an integration method of
metabolic maps into TPS, overcoming the absence of
DICOM 3.0 standard for MRSI, to guide the simultan-
eous integrated boost. We then compare dosimetry
plans of standard 60-Gy treatment in 3D conformational
radiotherapy (60-Gy 3D-CRT), 60-Gy in IMRT and the
treatment with the dose escalation of 72 Gy in
SIB-IMRT. The method that we described in this article
can be used for future prospective trials integrating MR
spectroscopy in radiotherapy planning treatments.
Methods
Patients
The pre-RT data were from 16 patients enrolled in a
prospective clinical trial on farnesyl-transferase inhibi-
tors (FTI) [19] associated with radiotherapy to treat glio-
blastoma. The trial was approved by the local ethics
committee and patients provided their written informed
consent. They received FTI and standard 3D-CRT. We
prospectively performed MRSI acquisition before radio-
therapy on this homogeneous group at the same session
time that the classical MRI sequences.
Data acquisition
For all 16 GMB patients, MR imaging was performed on
a 1.5 T Magnetom Avanto Siemens scanner (Erlangen,
Germany). Pre- and post- gadolinium injected (2 mL/kg
body weight) T1-weighted (T1–Gd) and Turbo-Spin-Echo
T2-weighted (T2) images were acquired for anatomic MR
evaluation with voxel resolution of 0.90x0.90x3.00 mm3.
3D-chemical-shift imaging (3D-CSI) for MRSI acquisi-
tion consisted of three phase-encoded gradients prior to
read-out, resulting in a scan time of 8 min. MRSI acqui-
sition consisted of a Spin-Echo-based sequence with the
following parameters: TR/TE = 1500 ms/135 ms for lac-
tate detection, and four excitations,FOV was set at
100×100 mm2 for a CSI matrix of 16×16, with eight
slices of 25.0 mm thickness, resulting in voxel resolution
of 6.25×6.25×25.0 mm3, i.e. 1 cm3. The 3D-CSI box was
positioned to cover the majority of abnormalities and
normal appearing tissue, while avoiding regions that
could corrupt the spectra - such as bone and subcutane-
ous lipids. Saturation bands were also positioned around
the volume of interest (VOI) to suppress signals from
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in vivo fat suppression.
CT simulation images for RT planning of all 16 GBM
patients were acquired in helical mode with voxel reso-
lution of 0.98×0.98×2.50 mm3.
Data processing
The spectroscopic processing protocol consisted of water
substraction, low-pass filtering, frequency shift correction,
baseline correction, phase correction and curve fitting in
the frequency domain. These steps of spectra processing
were performed with the Siemens Syngo MR B17 Spectros-
copy application (Erlangen, Germany).
Consistency analysis
After image processing, additional information specific
to MRSI abnormalities was embedded in the normalized
and segmented anatomic–metabolic images. Accuracy of
automated fusion between CT and anatomic MR images is
given to be submillimeter and subdegree with Syntegra
toolbox (Pinnacle software version 8.0 m, Philips Medical
Systems, Milpitas, CA) [23]. We found it relevant to check
all 16 patients’ data sets to determine if normalization and
threshold-based segmentation could wrongly influence the
fusion process between CT scans and anatomic-metabolic
images. Reliability and repeatability of the fusion were
assessed for each patient’s data with 10 successive co-
registration transformations. The result of the fusion
process was visually validated. For consistency analysis, the
means of standard deviations (SD) and the means of
maximum differences between translation and rotation
parameters, along the x (left–right), y (anterior–posterior),
and z (head–feet) axes were computed.
Dose-plan comparisons: 60-Gy 3D-C RT, 60-Gy IMRT and
72-Gy SIB-IMRT
For the treatment plans delivering 60 Gy, i.e. 60-Gy
3D-CRT and 60-Gy IMRT, the gross target volume
(GTV1) was defined as the anatomical contrast-
enhancing tumor visible on the T1–Gd images. The clin-
ical target volume (CTV1), representing the subclinical
tumor involvement, was defined as GTV1 + 17.0-mm ex-
pansion including the edema visible on the T2-weighted
images. The planning target volume (PTV1) was defined
as CTV1 + 3.0-mm margin. The dose calculation was
performed according to the conventional prescription of
60 Gy delivered in fractions of 2 Gy for the PTV1.
For the 72-Gy SIB-IMRT treatment plan, the GTV2
was defined as the MRSI abnormalities (Cho/NAA ≥
2.00). The CTV2 was defined as the GTV2 + 7.0-mm ex-
pansion including the contrast-enhancing tumor visible
on the T1–Gd images. The PTV2 was defined as the
CTV2 + 3.0-mm margin. The dose prescription was the
following: 60 Gy on the PTV1 as defined above and72 Gy on the PTV2 (SIB) delivered in fractions of
2.4 Gy.
We wanted to use the radiobiological advantages of an
integrated boost,and therefore, taking into account the
alpha/beta = 3 as calculated with the LQ model and the
dose equivalent for tumor repopulation, 80 Gy as the 2 Gy
per day are equivalent to 30 fractions of 2.4 Gy [24].
The TPS used in this study was Pinnacle version
8.0 m (Philips Medical Systems, Milpitas, CA).
The dose was calculated with the collapsed cone
convolution-superposition model. For SIB-IMRT, we
used the Direct Machine Parameter Optimization mod-
ule, which directly optimizes the number of monitor
units and the multileaf collimator leaves.
For comparison with the treatment plans delivering
60 Gy (60-Gy 3D-CRT and 60-Gy IMRT), six different
beam configurations of 72-Gy SIB-IMRT, for all 16
patients’ data sets, were tested: 96 dose-plans were then
simulated. The six different beam configurations con-
sisted of the following: configuration A = 3 coplanar
beams, configuration B = 3 coplanar beams with different
angles from configuration A, configuration C = 5 coplanar
beams, configuration D = 7 coplanar beams, configuration
E = 9 coplanar beams and configuration F = 5 non-coplanar
beams (3 coplanar and 2 non-coplanar beams).
The treatment plans delivering 60 Gy (60-Gy 3D-CRT
and 60-Gy IMRT) and the 72-Gy SIB-IMRT plans were
compared using the following criteria:
 Target coverage (I1), conformity index (I2), and
conformation number (CN) for quantifying the
degree of conformity [25]:
I1 ¼ PTV95%=VTOT PTV
I2 ¼ PTV95%=VISO 95
PTV95% ¼ Target volume ðPTVÞ receiving
95% of the prescription dose
VTOT PTV ¼ Total volume of target ðPTVÞ
VISO 95 ¼ Isodose volume enclosed by 95%
of the prescription dose
CN ¼ I1  I2
 Doses received by OAR: maximum dose at 1% of the
optic chiasm and brainstem.
 The dose-volumes of interest for the normal brain
were 18, 36, and 50 Gy given relative to the volume
of normal brain (V18, V36 and V50).
Statistical analysis
Continuous variables were described as their medians
and range. A Wilcoxon test compared the paired data.
All p-values were two-sided, and for all statistical tests,
differences were considered significant at the 5% level.
Stata (StataCorp LP, Texas, USA) was used for all statis-
tical analyses.
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MRSI integration into TPS
MRSI acquisition from all patients resulted in 3652
voxels (mean = 228.3, SD = 55.6), The Cho/NAA ratio
was thoroughly reviewed on a voxel-by-voxel basis:
3120 voxels were considered for the computation of
metabolite Cho/NAA maps. Both MR images (Figure 1,
first row) and 3D-MRSI were acquired in the same
plane in order for co-registration to occur, and the
resulting snapshots consisted of anatomic–metabolic
images coded under the red–green–blue (RGB) color-
space with a DICOM extension format file, but these
were not compatible for integration into TPS (Figure 1,
third row).
These anatomic–metabolic images were processed
with scripts written in MatlabW (MathWorks, Inc.,Figure 1 3D-MRSI acquisition before radiation therapy treatment of a
located in the right capsulo-thalamic region (first row, the volume of
showing contrast-enhancing disease, the MRSI volume of interest is defined
observed, the voxel is rejected (green frame on second row). The anatomic
interest (third row), the maximum Cho/NAA ratio values are encoded in re
The first two metabolite maps which present ratios of Cho/NAA≥ 2.00 sug
ratio of Cho/NAA≥ 2.00 are obtained after normalization and threshold ba
highlighted in red (last row). Note on the first image (last row) that the loc
contrast-enhancing area.Natick, USA) for integration into TPS. For the image-
processing normalization step, the separation of anatom-
ical MR images from the color metabolite ratio maps
was made. Conversion of the metabolite ratio maps from
RGB to hue-saturation-value (HSV) color-space [26] was
performed to retrieve a single quantitative value (hue)
from the metabolic map, which was proportional to
Cho/NAA. The Siemens Syngo MR B17 Spectroscopy
application (Erlangen, Germany) provided the local max-
imum of Cho/NAA for each CSI slice (i.e. the red color
on the corresponding color table), these values were
used as inputs to compute global normalization across
the entire 3D-MRSI volume of acquisition. The same
principle of color-space conversion is possible for other
color tables from different MR spectroscopy post-
treatment softwares.53 year-old unresected patient with confirmed glioblastoma
acquisition is framed in red). On the T1-Gd anatomic MR images
on a voxel by voxel basis,when alteration of metabolites spectra is
-metabolic maps are computed from the above defined volume of
d color and are respectively from left to right 2.27, 2.30, 1.52 and 1.15.
gest metabolic tumor activity. Regions of interest corresponding to
sed segmentation from the anatomic-metabolic images, these ROIs are
ation of the abnormal spectroscopic region is different and below the
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regions, the previously normalized maps were segmented
with a threshold value of Cho/NAA ≥ 2.00 [20]. Such seg-
mented regions of interest, with abnormal metabolite index
ratios, were then re-mapped onto respective anatomical
MR images (Figure 1, last row) with smooth linear
interpolation to the final resolution of anatomical MR
images. In this study, the 3D-MRSI volume represented
24.84% and 13.63% of the T1–Gd and hyper-T2 volumes,
respectively (range: 2.22–54.85%). The integration was fina-
lized with a copy of the DICOM headers from the T1–Gd
images into the headers of the anatomic–metabolic images.
These normalized and segmented anatomic–metabolic
images were generated for all patients, and were success-
fully imported for fusion with planning CT scans under dif-
ferent TPS and evaluation software for RT (Pinnacle
v8.0 m, Eclipse v8.9 and Artiview v2.6).
To summarize, the flow chart of image-processing steps
that integrated MRSI-defined regions with abnormal Cho/
NAA ratio values into RT TPS is detailed in Figure 2.Snapshots saved
under unsigned 8-bits RGB
(non DICOM standard
Anatomical MR images
registered on CSI box
Step D
Segmented metabolite
Cho/NAA maps at the 
pathological threshold of 2.00 are 
registered on anatomical MR 
images (compatible with TPS)
Step C
Figure 2 Flow chart of the image processing steps to integrate MRSI-Consistency analysis of MRSI integration into TPS
Results for the reliability and repeatability of the image
fusion (10 successive co-registration transformations on
each patient’s data) were the following: means SD were
found to be 0.19 mm, 0.25 mm, 0.39 mm, 0.25°, 0.37°,
and 0.29° and means of maximum differences were
found to be 0.59 mm, 0.49 mm, 0.83 mm, 0.82°, 1.15°,
and 0.94°,respectively for each translation and each rota-
tion parameter, along the x (left–right), y (anterior–pos-
terior), and z (head–feet) axes.
Dose-plan comparisons between 60-Gy 3D-CRT, 60-Gy
IMRT and 72-Gy SIB-IMRT
96 SIB-IMRT treatment plans were simulated and com-
pared with 16 plans of 60-Gy IMRT and 16 standard
3D-CRT plans (Figure 3). Median volumes of PTV1 and
PTV2 were respectively 307.76 cm3 (range: 84.52–
586.96 cm3) and 97.63 cm3 (range: 34.32–231.17 cm3).
Considering the PTV2 of the SIB-IMRT treatment
plans, I1, I2, and CN were evaluated and configuration)
Normalized metabolite
Cho/NAA maps according to
local maximum of each CSI slice
Normalized metabolite
Cho/NAA maps across whole
CSI VOI according to global 
maximum ratio value




defined regions with abnormal Cho/NAA ratio values into RT TPS.
(a) (b) (c)
Figure 3 Comparison of dose plans between 60-Gy 3D-CRT, 60-Gy IMRT and 72-Gy SIB-IMRT. 60-Gy 3D-CRT and 60-Gy IMRT plans
(respectively Figures 3a and 3b) have one PTV1 color-washed in blue. The integration of Cho/NAA abnormal volumes defines new target
relative to MRSI, i.e. PTV2 color-washed in red (Figure 3c), PTV1 is the same. The isodoses of 68.4 Gy (thick red isodose) and 57 Gy (thick dark blue
isodose) represent 95% of the prescribed dose respectively 72 Gy and 60 Gy on the PVT2 and PTV1. The isodose volumes of 54 Gy (pink), 50 Gy
(green), 36 Gy (purple) and 18 Gy (light blue) for organs at risk sparing are also plotted.
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D, E, and F, but higher I1, I2, and CN were found com-
pared with the configuration B (respectively, 0.97 vs
0.95, p = 0.005,0.79 vs 0.74, p = 0.030 and 0.75 vs 0.68,
p = 0.034). Configuration C was then chosen for dose-
plan comparison with standard 60-Gy 3D-CRT and 60-
Gy IMRT with 5 beam configuration.
Considering the PTV1, the configuration C shows no
significant difference with configurations A, D, E and F
but higher I1, I2 and CN are found compared with the
configuration B (respectively, 0.97 vs 0.95, p = 0.005,0.88
vs 0.84, p = 0.013 and 0.85 vs 0.82, p = 0.001). I1, I2 and
CN for PTV1 are compared between 60-Gy 3D-CRT,
60-Gy IMRT and 72-Gy SIB-IMRT (configuration C).
There is no significant difference for I1 (0.98, 0.95 vs
0.97, p > 0.255) but 60-Gy IMRT and 72-Gy SIB-IMRT
plans performed significantly better for I2 and CN
(respectively, 0.91, 0.88 vs 0.75, p < 0.010 and 0.84, 0.85
vs 0.72, p < 0.035).
When comparing the maximum dose received by
OAR, there was no statistically significant difference be-
tween 60-Gy 3D-CRT, 60-Gy IMRT and 72-Gy SIB-
IMRT for the optic chiasm (p > 0.088, Figure 4a). Com-
pared to 60 Gy 3D-CRT, 60-Gy IMRT and 72-Gy SIB-
IMRT significantly lowered the dose to the brainstem
(p < 0.001, Figure 4b).
For doses relative to the normal brain (Figure 4c), the
dose-volume V18 was not significantly different, but V36
and V50 were significantly lower with 60-Gy IMRT and
72- Gy SIB-IMRT (p < 0.05 and p < 0.001).Discussion
In this paper, we described an integration method of
MRSI for radiotherapy treatment planning in order to
perform a clinical trial for glioblastoma dose painting.At a time when delivering a higher dose to such radio-
resistant tumors is possible with IMRT, defining the op-
timal target is of paramount importance.
Several studies with additional boost showed good tol-
erance for dose escalation [27] and sometimes improved
tumor control [3,28-30] but they were not systematically
in concomitance with temozolomide and did not per-
form selective simultaneous integrated boost according
to functional or metabolic imaging modalities; to our
knowledge the only comparable approach was published
by Piroth et al. [27], who described a prospective phase
II study that defined the dose escalation (total dose of
72 Gy) with an integrated boost on active tumor as char-
acterized by positron emission tomography (PET) using
O-(2-[18 F]fluoroethyl)-L-tyrosine (FET), for which the
results of survival data were comparable to standard
treatment [1].
Despite the information contained in MRSI for pre-
dicting the site of relapse after radiotherapy [17,20],
3D-MRSI still remains a challenging modality to inte-
grate into TPS. Several attempts have been performed in
the last decade [31,32], also in the radiosurgery field
[33], but the innovative aspects of the MR spectroscopy
integration presented here are the following: a) it is a
method for three-dimensional MR spectroscopy that pro-
vides global normalization and threshold-based segmenta-
tion of the whole 3D-CSI volume of interest,b) it integrates
metabolite ratio maps into TPS using co-registration with
anatomic MR images, and c) it results in MR spectroscopic
pre-defined regions ready to be contoured.
In this study, a consistency analysis was performed to as-
sess the impact of combining MR anatomic and metabolic
information on fusion with CT scans, as both MR and
MRSI modalities were gathered in the same set of images.
As reliable integration of valuable biological target
volumes specific to MRSI into TPS was reached, a








V18 (18 Gy) V36 (36 Gy) V50 (50Gy)
60-Gy 3D-CRT 60-Gy IMRT 72-Gy SIB-IMRT 
(c)








P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14 P15 P16
60-Gy 3D-CRT 60-Gy IMRT 72-Gy SIB-IMRT








P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14 P15 P16








Figure 4 Comparison of the doses received by OAR between 60-Gy 3D-CRT, 60-Gy IMRT and 72-Gy SIB-IMRT for all patients
(P1 to P16). Doses relative to 60-Gy 3D-CRT are drawn in white, grey for 60-Gy IMRT and black for 72-Gy SIB-IMRT. No significant difference is
found when considering the maximum dose received by 1% of the optic chiasm (41.63 vs 45.47 and 42.08 Gy, p > 0.088) (Figure 4a). For the
brainstem, the maximum dose received by 1% of the organ is significantly lower (57.01 vs 44.30 and 44.00 Gy, p < 0.001) in 60-Gy IMRT and 72-Gy
SIB-IMRT (Figure 4b). Histograms of dose-volumes relative to normal brain comparing 60-Gy 3D-CRT (white), 60-Gy IMRT (grey) and 72-Gy SIB-
IMRT (balck) are shown on Figure 4c. No significant difference is found when considering the V18 (p > 0.326). 60-Gy IMRT and 72-Gy SIB-IMRT
were significantly smaller for V36 and V50 (19 and 20 vs. 23%, p = 0.049,7 and 7 vs. 12%, p < 0.001). No significant differences for V36 and V50
were found between 72-Gy SIB-IMRT and 60-Gy IMRT (p = 0.605).
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on the OAR of dose escalation. SIB-IMRT allowed us to
perform dose painting by contours for optimal irradi-
ation of target volumes and optimal sparing of OAR
[34]. Protection of normal brain tissue is of particular
importance for tolerance to dose increases and to pre-
vent radiation necrosis and neurocognitive deficits, as
these are significantly correlated with the dose received
by the normal brain [35]. Thus, a difficult compromise
between radiation necrosis, neurocognitive impairment
and tumor control has to be achieved. Although the
dose is increased on the target volume, the dose
received by OAR is either equivalent (optical chiasm)
or significantly lowered with the MRSI guided 72-Gy
SIB-IMRT compared to 60-Gy 3D-CRT (brainstem and
normal brain) thanks to the IMRT technique. The
repercussions of normal brain irradiation for patientswith GBM will be more of an issue if patient survival is
extended by dose escalation to regions that have a high
risk of relapse.Conclusions
We describe a reliable method to integrate 3D-MRSI for
dose escalation on regions of high-risk of relapse while op-
timizing OAR sparing. This work represents a novel ap-
proach to the treatment of glioblastoma and is the basis of
a multi-institutional phase-III prospective clinical trial,
which is currently underway to compare conventional
treatment delivering 60-Gy versus 72-Gy SIB-IMRT
guided by MRSI. This method could also be the basis of
other innovative trials integrating MRSI in radiotherapy
treatment planning but also in neuronavigation system to
improve the GBM resection or guide biopsies.
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